HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by van Bekkum, D. W. Search for Related Content PubMed PubMed Citation Articles by van Bekkum, D. W.

(Journal of Leukocyte Biology. 2002;72:609-620.)
© 2002 by Society for Leukocyte Biology

Experimental basis of hematopoietic stem cell transplantation for treatment of autoimmune diseases

Crucell B.V., Leiden, The Netherlands

Correspondence: D. W. van Bekkum, Crucell B.V., P.O. Box 2048 2301 CA, Leiden, The Netherlands

Experiments with animal models of autoimmune disease provided the rational and stimulus for the current, clinical studies of autologous stem cell transplantation for the treatment of a variety of severe, refractory, autoimmune diseases. The discoveries that led to the recognition of the key role of hematopoietic stem cells and the successful treatment of autoimmune diseases with bone marrow transplants are reviewed. The relevance of spontaneous and induced autoimmune disease models for the development of clinical treatment regimens is discussed. Most of the investigations with autologous stem cell transplantation have been performed with induced autoimmune disorders: in rats with adjuvant arthritis and in rats or mice with experimental, allergic encephalomyelitis, the current model for multiple sclerosis. The main aspects of this translational research were the conditioning regimens and the degree of T cell depletion of the graft as determinants of remission induction and the incidence of relapses. The emerging recommendations are compared with the outcome so far of the clinical studies.

Key Words: transplants • bone marrow • arthritis • encephalomyelitis

This article has been cited by other articles:

				K. S. Lang, M. Recher, A. A. Navarini, S. Freigang, N. L. Harris, M. van den Broek, B. Odermatt, H. Hengartner, and R. M. Zinkernagel Requirement for Neutralizing Antibodies to Control Bone Marrow Transplantation-Associated Persistent Viral Infection and to Reduce Immunopathology J. Immunol., October 15, 2005; 175(8): 5524 - 5531. [Abstract] [Full Text] [PDF]

				I. Bot, J. Guo, M. Van Eck, P. J. Van Santbrink, P. H. E. Groot, R. B. Hildebrand, J. Seppen, T. J. C. Van Berkel, and E. A. L. Biessen Lentiviral shRNA silencing of murine bone marrow cell CCR2 leads to persistent knockdown of CCR2 function in vivo Blood, August 15, 2005; 106(4): 1147 - 1153. [Abstract] [Full Text] [PDF]

				G. F. Beilhack, R. R. Landa, M. A. Masek, and J. A. Shizuru Prevention of Type 1 Diabetes with Major Histocompatibility Complex-Compatible and Nonmarrow Ablative Hematopoietic Stem Cell Transplants Diabetes, June 1, 2005; 54(6): 1770 - 1779. [Abstract] [Full Text] [PDF]

				W. Sun, U. Popat, G. Hutton, Y. C. Q. Zang, R. Krance, G. Carrum, G. A. Land, H. Heslop, M. Brenner, and J. Z. Zhang Characteristics of T-cell receptor repertoire and myelin-reactive T cells reconstituted from autologous haematopoietic stem-cell grafts in multiple sclerosis Brain, May 1, 2004; 127(5): 996 - 1008. [Abstract] [Full Text] [PDF]

				O. Y. Jones, A. Steele, J. M. Jones, Y. Marikar, Y. Chang, A. Feliz, R. A. Cahill, and R. A. Good Nonmyeloablative Bone Marrow Transplantation of BXSB Lupus Mice Using Fully Matched Allogeneic Donor Cells from Green Fluorescent Protein Transgenic Mice J. Immunol., May 1, 2004; 172(9): 5415 - 5419. [Abstract] [Full Text] [PDF]